指南与共识其他结缔组织病

EULAR白塞综合征管理推荐:2025年更新

EULAR recommendations for the management of Behçet's syndrome: 2025 update.
指南 / 共识 · Ann Rheum Dis · 2026-03-23

该更新基于EULAR标准操作流程,由11国29名成员组成的工作组通过Delphi调查和系统文献综述修订推荐。最终形成5条总体原则和12条推荐,按器官受累分类,其中1条为新推荐、7条为修改推荐。推荐强调个体化治疗、多学科协作和医患共同决策。

要点

  • 皮肤黏膜和关节受累首选秋水仙碱,难治者可用阿普米司特或TNFα抑制剂。
  • 器官受累者推荐糖皮质激素联合免疫抑制剂快速诱导缓解。
  • 器官或危及生命表现者鼓励早期使用TNFα单克隆抗体。

核心结论

  • 更新后的EULAR推荐为白塞综合征管理提供指导,旨在改善患者照护质量。

研究设计与样本

  • 工作组由11个国家29名成员组成,包括19名风湿科医生、2名眼科医生、1名皮肤科医生、1名消化科医生、1名神经科医生、1名卫生专业人员、2名患者研究伙伴和2名Emerging EUlar NETwork成员。

主要发现

  • 更新推荐包括5条总体原则和12条推荐,按器官受累列表。
  • 12条推荐中1条为新推荐,7条为修改推荐,4条仅更改措辞。

关键数值与推荐

  • 总体原则强调识别复发缓解病程,根据疾病活动度和预后风险因素个体化治疗,并重视多学科方法、患者教育和共享决策。
  • 皮肤黏膜和关节受累推荐秋水仙碱为一线治疗,难治患者推荐阿普米司特和免疫抑制剂如TNFα抑制剂。
  • 器官受累患者推荐更积极的糖皮质激素和免疫抑制剂治疗以快速诱导缓解,器官或危及生命表现者鼓励早期使用TNFα单克隆抗体。

临床怎么用

  • 临床中应根据器官受累情况选择治疗:皮肤黏膜和关节受累首选秋水仙碱,器官受累者积极使用激素和免疫抑制剂,高危者早期启用TNFα单克隆抗体。

局限性

  • 推荐基于新证据和专家意见更新,但原文未报告系统文献综述的具体纳入研究数量或证据等级细节。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: This study aims to update the European Alliance of Associations for Rheumatology (EULAR) recommendations for the management of Behçet's syndrome according to the updated EULAR standard operating procedures. METHODS: The task force comprised 29 members from 11 countries, including 19 rheumatologists, 2 ophthalmologists, 1 dermatologist, 1 gastroenterologist, 1 neurologist, 1 health professional, 2 patient research partners, and 2 Emerging EUlar NETwork members. Research questions were proposed by the task force through a Delphi survey and formulated into patients, interventions, comparison, and outcomes (PICO) questions for the systematic literature review. The results of the systematic literature review were discussed among the task force members. Previous recommendations and overarching principles were modified, and new recommendations were developed as needed. The updated recommendations were voted, and the levels of evidence and levels of agreement were determined. RESULTS: The updated recommendations consist of 5 overarching principles and 12 recommendations that were tabulated according to organ involvement. Among the 12 recommendations, 1 was a new recommendation, 7 recommendations were modified, and only the wording was changed in 4 recommendations. The overarching principles focus on the importance of recognising the relapsing and remitting disease course and individualising treatment according to disease activity and prognostic risk factors, and emphasise the importance of a multidisciplinary approach, patient education, and shared decision making for optimal care. For mucocutaneous and joint involvement, colchicine is recommended as the first-line treatment modality. Apremilast and immunosuppressives such as tumour necrosis factor alpha (TNFα) inhibitors are recommended for refractory patients. For patients with organ involvement, more aggressive treatment with glucocorticoids and immunosuppressives is recommended for rapid induction of remission. Early use of monoclonal antibodies against TNFα is encouraged in patients with organ or life-threatening manifestations. CONCLUSIONS: These recommendations, which were updated based on new evidence and expert opinion, provide guidance for all stakeholders involved in the management of patients with Behçet's syndrome to improve the quality of care of these patients.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Hatemi G, Ramiro S, Ozguler Y, et al. EULAR recommendations for the management of Behçet's syndrome: 2025 update. Ann Rheum Dis. 2026. PMID: 41876291. doi:10.1016/j.ard.2026.02.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。